By Infinium Global Research Aug, 2020
The Global Therapeutic Vaccines Market is
expected to grow at a CAGR of 12.50% between 2019 and 2025 in terms of value.
The major driving factor such as the increasing occurrence of cancer,
cardiovascular diseases, HIV infection, and various chronic diseases are
boosting the therapeutic vaccines market. The World Health Organization reports
infectious diseases to kill more than 17 million people a year. 30 new diseases
have emerged in the last 20 years. According to WHO, the common vaccine-preventable diseases include diphtheria, Haemophilus influenza serotype b
infection, hepatitis B, measles, meningitis, mumps, pertussis, poliomyelitis,
rubella, tetanus, tuberculosis, and yellow fever. In addition, an increase in
funding from the government for vaccine development and growing awareness among
people for severe disease are the key factors escalating the growth of the therapeutic vaccines market. Moreover, the unprecedented levels of urbanization
and swelling populations of city dwellers inescapably pose greater risks of
infectious disease transmission, which in turn, is likely to drive the growth
of the market. However, the high cost associated with treatment is expected to
hinder the growth of the therapeutic vaccines market. Moreover, various
pharmaceutical players in this market are extensively researching on the
research & development activities to develop novel vaccines for several
diseases that may create growth opportunities for the therapeutic vaccines market
in the near future.
The global therapeutic vaccines market is
segmented based on Vaccines Type, Disease Indication, Administration, and by end-user. Vaccine type covered in the report includes autoimmune diseases
vaccines, neurological disease vaccines, chronic disease vaccines and infectious
diseases vaccines. Based on the market study the infectious diseases vaccines
holds the largest share and has high growth potential, growing with a CAGR of
12.01% in the forecast period due to the rising population suffering from autoimmune diseases and infectious diseases. Based on the disease indication
the segment is classified into pneumococcal disease, DTP, influenza, human
papillomavirus, meningococcal disease, polio, hepatitis, MMR, varicella, and
dengue. The DTP lead segment holds the largest share of 16.27% in 2018 owing to
high incidences of Diphtheria, Tetanus, Pertussis among children, and a large
number of government initiatives for the eradication of these diseases. By
route of administration, the market is categorized in Intramuscular and
subcutaneous administration, Oral Administration, and others. Based on the
market study, the Intramuscular and subcutaneous administration lead the
segment and is expected to grow with a significant CAGR of 12.92% in the forecast
period as vaccines Hepatitis A, Human papillomavirus (HPV2 and HPV4) and
Meningococcal polysaccharide (MPSV4) is administered by intramuscular and
subcutaneous routes. Among the end-users, the pediatric segment holds the dominant
share of 63.37% in the global therapeutic vaccines market.
Among the geographies, North America is the
leading contributor to the therapeutic vaccines market. The U.S has the largest
market share in the North America region. Developed medical and healthcare
infrastructure and increasing funding for research and development activities
are the few factors augmenting the growth in the North America region. On the
other hand, the Asia-Pacific region is anticipated to be the fastest-growing market in the upcoming years owing to the increasing prevalence of various diseases,
rising disposable income and rapidly growing aging population.